ID   RET_HUMAN               Reviewed;        1072 AA.
AC   P07949-2;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 3.
DT   12-OCT-2022, entry version 268.
DE   RecName: Full=Isoform 2 of Proto-oncogene tyrosine-protein kinase receptor Ret {ECO:0000305};
DE            EC=2.7.10.1;
DE   AltName: Full=Cadherin family member 12;
DE   AltName: Full=Proto-oncogene c-Ret;
DE   Contains:
DE     RecName: Full=Soluble RET kinase fragment;
DE   Contains:
DE     RecName: Full=Extracellular cell-membrane anchored RET cadherin 120 kDa fragment;
DE   Flags: Precursor;
GN   Name=RET {ECO:0000312|HGNC:HGNC:9967};
GN   Synonyms=CDHF12, CDHR16, PTC, RET51;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Prostate;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT CYS-982.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-280 (ISOFORMS 1/2).
RX   PubMed=2660074;
RA   Takahashi M.;
RT   "Isolation of ret proto-oncogene cDNA with an amino-terminal signal
RT   sequence.";
RL   Oncogene 4:805-806(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 255-1114 (ISOFORM 1).
RX   PubMed=3078962;
RA   Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., Hiai H.;
RT   "Cloning and expression of the ret proto-oncogene encoding a tyrosine
RT   kinase with two potential transmembrane domains.";
RL   Oncogene 3:571-578(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 588-1063 (ISOFORM 2), AND CHROMOSOMAL
RP   TRANSLOCATION WITH TRIM27.
RX   PubMed=3037315; DOI=10.1128/mcb.7.4.1378-1385.1987;
RA   Takahashi M., Cooper G.M.;
RT   "ret transforming gene encodes a fusion protein homologous to tyrosine
RT   kinases.";
RL   Mol. Cell. Biol. 7:1378-1385(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL
RP   TRANSLOCATION WITH GOLGA5.
RC   TISSUE=Fibroblast;
RX   PubMed=2734021;
RA   Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.;
RT   "Activation of the ret-II oncogene without a sequence encoding a
RT   transmembrane domain and transforming activity of two ret-II oncogene
RT   products differing in carboxy-termini due to alternative splicing.";
RL   Oncogene 4:789-794(1989).
RN   [8]
RP   ERRATUM OF PUBMED:2734021.
RA   Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.;
RL   Oncogene 4:1415-1415(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL
RP   TRANSLOCATION WITH CCDC6.
RC   TISSUE=Thyroid papillary carcinoma;
RX   PubMed=2406025; DOI=10.1016/0092-8674(90)90659-3;
RA   Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R.,
RA   Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G.;
RT   "PTC is a novel rearranged form of the ret proto-oncogene and is frequently
RT   detected in vivo in human thyroid papillary carcinomas.";
RL   Cell 60:557-563(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-770 (ISOFORMS 1/2), AND CHROMOSOMAL
RP   TRANSLOCATION WITH PCM1.
RX   PubMed=10980597; DOI=10.1038/sj.onc.1203772;
RA   Corvi R., Berger N., Balczon R., Romeo G.;
RT   "RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma.";
RL   Oncogene 19:4236-4242(2000).
RN   [11]
RP   CHROMOSOMAL TRANSLOCATION WITH TRIM33 AND TRIM24.
RX   PubMed=10439047; DOI=10.1038/sj.onc.1202824;
RA   Klugbauer S., Rabes H.M.;
RT   "The transcription coactivator HTIF1 and a related protein are fused to the
RT   RET receptor tyrosine kinase in childhood papillary thyroid carcinomas.";
RL   Oncogene 18:4388-4393(1999).
RN   [12]
RP   PHOSPHORYLATION AT TYR-1015 AND TYR-1062.
RX   PubMed=11061555; DOI=10.1210/jcem.85.10.6882;
RA   Salvatore D., Barone M.V., Salvatore G., Melillo R.M., Chiappetta G.,
RA   Mineo A., Fenzi G., Vecchio G., Fusco A., Santoro M.;
RT   "Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and
RT   ret-derived oncoproteins.";
RL   J. Clin. Endocrinol. Metab. 85:3898-3907(2000).
RN   [13]
RP   PHOSPHORYLATION AT TYR-806; TYR-809; TYR-900; TYR-905; TYR-981; TYR-1015;
RP   TYR-1062; TYR-1090 AND TYR-1096.
RX   PubMed=14711813; DOI=10.1074/jbc.m312600200;
RA   Kawamoto Y., Takeda K., Okuno Y., Yamakawa Y., Ito Y., Taguchi R., Kato M.,
RA   Suzuki H., Takahashi M., Nakashima I.;
RT   "Identification of RET autophosphorylation sites by mass spectrometry.";
RL   J. Biol. Chem. 279:14213-14224(2004).
RN   [14]
RP   CHROMOSOMAL TRANSLOCATION WITH TRIM27.
RX   PubMed=12787916; DOI=10.1016/s0027-5107(03)00056-3;
RA   Saenko V., Rogounovitch T., Shimizu-Yoshida Y., Abrosimov A., Lushnikov E.,
RA   Roumiantsev P., Matsumoto N., Nakashima M., Meirmanov S., Ohtsuru A.,
RA   Namba H., Tsyb A., Yamashita S.;
RT   "Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid
RT   carcinoma from externally irradiated patient.";
RL   Mutat. Res. 527:81-90(2003).
RN   [15]
RP   RETRACTED PAPER.
RX   PubMed=16778204; DOI=10.1158/0008-5472.can-06-0228;
RA   Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M.,
RA   Carlomagno F., Santoro M., Fusco A.;
RT   "The receptor-type protein tyrosine phosphatase J antagonizes the
RT   biochemical and biological effects of RET-derived oncoproteins.";
RL   Cancer Res. 66:6280-6287(2006).
RN   [16]
RP   RETRACTION NOTICE OF PUBMED:16778204.
RX   PubMed=30552125; DOI=10.1158/0008-5472.can-18-3456;
RA   Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M.,
RA   Carlomagno F., Santoro M., Fusco A.;
RL   Cancer Res. 78:6907-6907(2018).
RN   [17]
RP   ACTIVITY REGULATION.
RX   PubMed=17884497; DOI=10.1016/j.bmcl.2007.07.104;
RA   Graham Robinett R., Freemerman A.J., Skinner M.A., Shewchuk L., Lackey K.;
RT   "The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET
RT   kinase inhibitors.";
RL   Bioorg. Med. Chem. Lett. 17:5886-5893(2007).
RN   [18]
RP   ACTIVITY REGULATION BY SORAFENIB.
RX   PubMed=17664273; DOI=10.1074/jbc.m703461200;
RA   Plaza-Menacho I., Mologni L., Sala E., Gambacorti-Passerini C., Magee A.I.,
RA   Links T.P., Hofstra R.M.W., Barford D., Isacke C.M.;
RT   "Sorafenib functions to potently suppress RET tyrosine kinase activity by
RT   direct enzymatic inhibition and promoting RET lysosomal degradation
RT   independent of proteasomal targeting.";
RL   J. Biol. Chem. 282:29230-29240(2007).
RN   [19]
RP   ACTIVITY REGULATION BY 3- AND 4-SUBSTITUTED BETA-CARBOLIN-1-ONES.
RX   PubMed=19053769; DOI=10.1021/jm8007823;
RA   Cincinelli R., Cassinelli G., Dallavalle S., Lanzi C., Merlini L.,
RA   Botta M., Tuccinardi T., Martinelli A., Penco S., Zunino F.;
RT   "Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and
RT   4-substituted beta-carbolin-1-ones.";
RL   J. Med. Chem. 51:7777-7787(2008).
RN   [20]
RP   INTERACTION WITH CD2AP, AND MUTAGENESIS OF LYS-758.
RX   PubMed=18753381; DOI=10.1523/jneurosci.2738-08.2008;
RA   Tsui C.C., Pierchala B.A.;
RT   "CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the regulation
RT   of ret signal transduction.";
RL   J. Neurosci. 28:8789-8800(2008).
RN   [21]
RP   INTERACTION WITH AIP.
RX   PubMed=19366855; DOI=10.1210/jc.2008-1980;
RA   Vargiolu M., Fusco D., Kurelac I., Dirnberger D., Baumeister R., Morra I.,
RA   Melcarne A., Rimondini R., Romeo G., Bonora E.;
RT   "The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon
RT   receptor-interacting protein to alter survivin availability.";
RL   J. Clin. Endocrinol. Metab. 94:2571-2578(2009).
RN   [22]
RP   INDUCTION BY NKX2-1; PHOX2B; SOX10 AND PAX3.
RX   PubMed=19853745; DOI=10.1016/j.jpedsurg.2008.11.055;
RA   Leon T.Y.Y., Ngan E.S.W., Poon H.-C., So M.-T., Lui V.C.H., Tam P.K.H.,
RA   Garcia-Barcelo M.M.;
RT   "Transcriptional regulation of RET by Nkx2-1, Phox2b, Sox10, and Pax3.";
RL   J. Pediatr. Surg. 44:1904-1912(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-696, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [24]
RP   FUNCTION IN DEVELOPMENT OF MECHANORECEPTORS.
RX   PubMed=20064382; DOI=10.1016/j.neuron.2009.12.014;
RA   Ma Q.;
RT   "RETouching upon mechanoreceptors.";
RL   Neuron 64:773-776(2009).
RN   [25]
RP   ACTIVITY REGULATION, AND REVIEW ON KINASE INHIBITORS.
RX   PubMed=20605972; DOI=10.1210/er.2009-0031;
RA   Ye L., Santarpia L., Gagel R.F.;
RT   "The evolving field of tyrosine kinase inhibitors in the treatment of
RT   endocrine tumors.";
RL   Endocr. Rev. 31:578-599(2010).
RN   [26]
RP   ACTIVITY REGULATION.
RX   PubMed=20409618; DOI=10.1016/j.ejmech.2010.03.017;
RA   Brandt W., Mologni L., Preu L., Lemcke T., Gambacorti-Passerini C.,
RA   Kunick C.;
RT   "Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-
RT   thienyl)nicotinonitrile scaffold.";
RL   Eur. J. Med. Chem. 45:2919-2927(2010).
RN   [27]
RP   FUNCTION IN PITUITARY.
RX   PubMed=20616503; DOI=10.1159/000318502;
RA   Garcia-Lavandeira M., Diaz-Rodriguez E., Garcia-Rendueles M.E.,
RA   Rodrigues J.S., Perez-Romero S., Bravo S.B., Alvarez C.V.;
RT   "Functional role of the RET dependence receptor, GFRa co-receptors and
RT   ligands in the pituitary.";
RL   Front. Horm. Res. 38:127-138(2010).
RN   [28]
RP   FUNCTION IN CELL ADHESION/MIGRATION.
RX   PubMed=20702524; DOI=10.1210/jc.2010-0771;
RA   Cockburn J.G., Richardson D.S., Gujral T.S., Mulligan L.M.;
RT   "RET-mediated cell adhesion and migration require multiple integrin
RT   subunits.";
RL   J. Clin. Endocrinol. Metab. 95:E342-E346(2010).
RN   [29]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19823924; DOI=10.1007/s10895-009-0548-x;
RA   Richardson D.S., Mulligan L.M.;
RT   "Direct visualization of vesicle maturation and plasma membrane protein
RT   trafficking.";
RL   J. Fluoresc. 20:401-405(2010).
RN   [30]
RP   ACTIVITY REGULATION.
RX   PubMed=21134556; DOI=10.1016/j.surg.2010.09.026;
RA   Samadi A.K., Mukerji R., Shah A., Timmermann B.N., Cohen M.S.;
RT   "A novel RET inhibitor with potent efficacy against medullary thyroid
RT   cancer in vivo.";
RL   Surgery 148:1228-1236(2010).
RN   [31]
RP   FUNCTION IN CELL ADHESION, FUNCTION IN APOPTOSIS, PROTEOLYTIC PROCESSING BY
RP   CASPASE-3 AT ASP-707 AND ASP-1017, MUTAGENESIS OF ASP-707; LYS-758 AND
RP   708-ALA--SER-1114, AND SUBUNIT.
RX   PubMed=21357690; DOI=10.1074/jbc.m110.195461;
RA   Cabrera J.R., Bouzas-Rodriguez J., Tauszig-Delamasure S., Mehlen P.;
RT   "RET modulates cell adhesion via its cleavage by caspase in sympathetic
RT   neurons.";
RL   J. Biol. Chem. 286:14628-14638(2011).
RN   [32]
RP   INTERACTION WITH PTK2/FAK1, AND FUNCTION IN PTK2/FAK1 PHOSPHORYLATION.
RX   PubMed=21454698; DOI=10.1074/jbc.m110.168500;
RA   Plaza-Menacho I., Morandi A., Mologni L., Boender P.,
RA   Gambacorti-Passerini C., Magee A.I., Hofstra R.M.W., Knowles P.,
RA   McDonald N.Q., Isacke C.M.;
RT   "Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming
RT   a direct and reciprocal RET-FAK transactivation mechanism.";
RL   J. Biol. Chem. 286:17292-17302(2011).
RN   [33]
RP   INTERACTION WITH GDNF, AND SUBCELLULAR LOCATION.
RX   PubMed=21994944; DOI=10.1074/jbc.m111.246413;
RA   Geng Z., Xu F.Y., Huang S.H., Chen Z.Y.;
RT   "Sorting protein-related receptor SorLA controls regulated secretion of
RT   glial cell line-derived neurotrophic factor.";
RL   J. Biol. Chem. 286:41871-41882(2011).
RN   [34]
RP   INTERACTION WITH GFRA1, AND SUBCELLULAR LOCATION.
RX   PubMed=23333276; DOI=10.1016/j.celrep.2012.12.011;
RA   Glerup S., Lume M., Olsen D., Nyengaard J.R., Vaegter C.B., Gustafsen C.,
RA   Christensen E.I., Kjolby M., Hay-Schmidt A., Bender D., Madsen P.,
RA   Saarma M., Nykjaer A., Petersen C.M.;
RT   "SorLA controls neurotrophic activity by sorting of GDNF and its receptors
RT   GFRalpha1 and RET.";
RL   Cell Rep. 3:186-199(2013).
RN   [35]
RP   INTERACTION WITH GFRAL, SUBCELLULAR LOCATION, FUNCTION, AND MUTAGENESIS OF
RP   TYR-1062.
RX   PubMed=28953886; DOI=10.1038/nature24042;
RA   Hsu J.Y., Crawley S., Chen M., Ayupova D.A., Lindhout D.A., Higbee J.,
RA   Kutach A., Joo W., Gao Z., Fu D., To C., Mondal K., Li B., Kekatpure A.,
RA   Wang M., Laird T., Horner G., Chan J., McEntee M., Lopez M.,
RA   Lakshminarasimhan D., White A., Wang S.P., Yao J., Yie J., Matern H.,
RA   Solloway M., Haldankar R., Parsons T., Tang J., Shen W.D., Alice Chen Y.,
RA   Tian H., Allan B.B.;
RT   "Non-homeostatic body weight regulation through a brainstem-restricted
RT   receptor for GDF15.";
RL   Nature 550:255-259(2017).
RN   [36]
RP   ERRATUM OF PUBMED:28953886.
RX   PubMed=29144449; DOI=10.1038/nature24481;
RA   Hsu J.Y., Crawley S., Chen M., Ayupova D.A., Lindhout D.A., Higbee J.,
RA   Kutach A., Joo W., Gao Z., Fu D., To C., Mondal K., Li B., Kekatpure A.,
RA   Wang M., Laird T., Horner G., Chan J., McEntee M., Lopez M.,
RA   Lakshminarasimhan D., White A., Wang S.P., Yao J., Yie J., Matern H.,
RA   Solloway M., Haldankar R., Parsons T., Tang J., Shen W.D., Alice Chen Y.,
RA   Tian H., Allan B.B.;
RT   "Non-homeostatic body weight regulation through a brainstem-restricted
RT   receptor for GDF15.";
RL   Nature 551:398-398(2017).
RN   [37]
RP   FUNCTION, AND INTERACTION WITH GFRAL.
RX   PubMed=28846097; DOI=10.1038/nm.4392;
RA   Mullican S.E., Lin-Schmidt X., Chin C.N., Chavez J.A., Furman J.L.,
RA   Armstrong A.A., Beck S.C., South V.J., Dinh T.Q., Cash-Mason T.D.,
RA   Cavanaugh C.R., Nelson S., Huang C., Hunter M.J., Rangwala S.M.;
RT   "GFRAL is the receptor for GDF15 and the ligand promotes weight loss in
RT   mice and nonhuman primates.";
RL   Nat. Med. 23:1150-1157(2017).
RN   [38]
RP   FUNCTION, INTERACTION WITH GFRAL, AND PHOSPHORYLATION AT TYR-905 AND
RP   TYR-1062.
RX   PubMed=28846099; DOI=10.1038/nm.4394;
RA   Yang L., Chang C.C., Sun Z., Madsen D., Zhu H., Padkjaer S.B., Wu X.,
RA   Huang T., Hultman K., Paulsen S.J., Wang J., Bugge A., Frantzen J.B.,
RA   Noergaard P., Jeppesen J.F., Yang Z., Secher A., Chen H., Li X., John L.M.,
RA   Shan B., He Z., Gao X., Su J., Hansen K.T., Yang W., Joergensen S.B.;
RT   "GFRAL is the receptor for GDF15 and is required for the anti-obesity
RT   effects of the ligand.";
RL   Nat. Med. 23:1158-1166(2017).
RN   [39] {ECO:0007744|PDB:2IVS, ECO:0007744|PDB:2IVT, ECO:0007744|PDB:2IVU, ECO:0007744|PDB:2IVV}
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 705-1013 ALONE AND IN COMPLEX WITH
RP   INHIBITORS, IDENTIFICATION BY MASS SPECTROMETRY, AND PHOSPHORYLATION AT
RP   TYR-900 AND TYR-905.
RX   PubMed=16928683; DOI=10.1074/jbc.m605604200;
RA   Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S.,
RA   Santoro M., Ibanez C.F., McDonald N.Q.;
RT   "Structure and chemical inhibition of the RET tyrosine kinase domain.";
RL   J. Biol. Chem. 281:33577-33587(2006).
RN   [40] {ECO:0007744|PDB:2X2K, ECO:0007744|PDB:2X2L, ECO:0007744|PDB:2X2M}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 705-1013 IN COMPLEX WITH
RP   INHIBITORS, ACTIVITY REGULATION, AND PHOSPHORYLATION AT TYR-905.
RX   PubMed=20117004; DOI=10.1016/j.bmc.2010.01.011;
RA   Mologni L., Rostagno R., Brussolo S., Knowles P.P., Kjaer S.,
RA   Murray-Rust J., Rosso E., Zambon A., Scapozza L., McDonald N.Q.,
RA   Lucchini V., Gambacorti-Passerini C.;
RT   "Synthesis, structure-activity relationship and crystallographic studies of
RT   3-substituted indolin-2-one RET inhibitors.";
RL   Bioorg. Med. Chem. 18:1482-1496(2010).
RN   [41] {ECO:0007744|PDB:2X2U}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-270, GLYCOSYLATION AT ASN-151,
RP   AND DISULFIDE BOND.
RX   PubMed=20473317; DOI=10.1038/nsmb.1808;
RA   Kjaer S., Hanrahan S., Totty N., McDonald N.Q.;
RT   "Mammal-restricted elements predispose human RET to folding impairment by
RT   HSCR mutations.";
RL   Nat. Struct. Mol. Biol. 17:726-731(2010).
RN   [42]
RP   REVIEW ON HSCR VARIANTS.
RX   PubMed=9359036;
RA   Hofstra R.M.W., Osinga J., Buys C.H.C.M.;
RT   "Mutations in Hirschsprung disease: when does a mutation contribute to the
RT   phenotype.";
RL   Eur. J. Hum. Genet. 5:180-185(1997).
RN   [43]
RP   REVIEW ON VARIANTS.
RX   PubMed=9067749;
RX   DOI=10.1002/(sici)1098-1004(1997)9:2<97::aid-humu1>3.0.co;2-m;
RA   Eng C., Mulligan L.M.;
RT   "Mutations of the RET proto-oncogene in the multiple endocrine neoplasia
RT   type 2 syndromes, related sporadic tumours, and Hirschsprung disease.";
RL   Hum. Mutat. 9:97-109(1997).
RN   [44]
RP   VARIANTS MEN2A/MTC TRP-611; SER-618; ARG-620; TYR-620 AND ARG-634.
RX   PubMed=8103403; DOI=10.1093/hmg/2.7.851;
RA   Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C.,
RA   Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Jr.;
RT   "Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.";
RL   Hum. Mol. Genet. 2:851-856(1993).
RN   [45]
RP   VARIANTS MEN2A GLY-618; 632-ASP--ARG-634; GLY-634; PHE-634; TYR-634 AND
RP   SER-634.
RX   PubMed=8099202; DOI=10.1038/363458a0;
RA   Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C., Gardner E.,
RA   Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A., Telenius H.,
RA   Tunnacliffe A., Ponder B.A.J.;
RT   "Germ-line mutations of the RET proto-oncogene in multiple endocrine
RT   neoplasia type 2A.";
RL   Nature 363:458-460(1993).
RN   [46]
RP   VARIANTS HSCR1 PRO-40; LEU-399; GLN-762; PRO-765; GLN-897; GLY-972 AND
RP   LEU-973.
RX   PubMed=7704557; DOI=10.1159/000472371;
RA   Yin L., Barone V., Seri M., Bolino A., Bocciardi R., Ceccherini I.,
RA   Pasini B., Tocco T., Lerone M., Cywes S., Moore S., Vanderwinden J.-M.,
RA   Abramowicz M.J., Kristoffersson U., Larsson L.T., Hamel B.C.J., Silengo M.,
RA   Martucciello G., Romeo G.;
RT   "Heterogeneity and low detection rate of RET mutations in Hirschsprung
RT   disease.";
RL   Eur. J. Hum. Genet. 2:272-280(1994).
RN   [47]
RP   VARIANT MEN2B THR-918.
RX   PubMed=7911697; DOI=10.1093/hmg/3.2.237;
RA   Eng C., Smith D.P., Mulligan L.M., Nagai M.A., Healey C.S., Ponder M.A.,
RA   Gardner E., Scheumann G.F., Jackson C.E., Tunnacliffe A., Ponder B.A.J.;
RT   "Point mutation within the tyrosine kinase domain of the RET proto-oncogene
RT   in multiple endocrine neoplasia type 2B and related sporadic tumours.";
RL   Hum. Mol. Genet. 3:237-241(1994).
RN   [48]
RP   VARIANTS MEN2A/MTC ARG-618; SER-618; PHE-620; ARG-620; PHE-634; GLY-634 AND
RP   TYR-634.
RX   PubMed=7915165; DOI=10.1093/hmg/3.4.635;
RA   Xue F., Yu H., Maurer L.H., Memoli V.A., Nutile-Mcmenemy N., Schuster M.K.,
RA   Browden D.W., Mao J.-I., Noll W.W.;
RT   "Germline RET mutations in MEN 2A and FMTC and their detection by simple
RT   DNA diagnostic tests.";
RL   Hum. Mol. Genet. 3:635-638(1994).
RN   [49]
RP   VARIANTS MTC/MEN2A TYR-609; ARG-618; SER-618 AND SER-620.
RX   PubMed=7849720; DOI=10.1093/hmg/3.10.1895;
RA   Blaugrund J.E., Johns M.M. Jr., Eby Y.J., Ball D.W., Baylin S.B.,
RA   Hruban R.H., Sidransky D.;
RT   "RET proto-oncogene mutations in inherited and sporadic medullary thyroid
RT   cancer.";
RL   Hum. Mol. Genet. 3:1895-1897(1994).
RN   [50]
RP   VARIANTS MTC, AND VARIANTS MEN2A.
RX   PubMed=7874109; DOI=10.1093/hmg/3.11.1939;
RA   Schuffenecker I., Billaud M., Calender A., Chambe B., Ginet N.,
RA   Calmettes C., Modigliani E., Lenoir G.M.;
RT   "RET proto-oncogene mutations in French MEN 2A and FMTC families.";
RL   Hum. Mol. Genet. 3:1939-1943(1994).
RN   [51]
RP   VARIANTS HSCR1 TRP-609; ARG-618 AND ARG-620, VARIANT MEN2A ARG-618, AND
RP   VARIANT MTC ARG-620.
RX   PubMed=7881414; DOI=10.1093/hmg/3.12.2163;
RA   Mulligan L.M., Eng C., Attie T., Lyonnet S., Marsh D.J., Hyland V.J.,
RA   Robinson B.G., Frilling A., Verellen-Dumoulin C., Safar A., Venter D.J.,
RA   Munnich A., Ponder B.A.J.;
RT   "Diverse phenotypes associated with exon 10 mutations of the RET proto-
RT   oncogene.";
RL   Hum. Mol. Genet. 3:2163-2167(1994).
RN   [52]
RP   VARIANT MEN2B THR-918.
RX   PubMed=7906866; DOI=10.1038/367375a0;
RA   Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T.,
RA   Luo Y., Pasini B., Hoeppener J.W.M., Ploos van Amstel H.K., Romeo G.,
RA   Lips C.J.M., Buys C.H.C.M.;
RT   "A mutation in the RET proto-oncogene associated with multiple endocrine
RT   neoplasia type 2B and sporadic medullary thyroid carcinoma.";
RL   Nature 367:375-376(1994).
RN   [53]
RP   VARIANTS HSCR1 PRO-765; GLN-897 AND GLY-972.
RX   PubMed=8114938; DOI=10.1038/367377a0;
RA   Romeo G., Ronchetto P., Luo Y., Barone V., Seri M., Ceccherini I.,
RA   Pasini B., Bocciardi R., Lerone M., Kaarlainen H., Martucciello G.;
RT   "Point mutations affecting the tyrosine kinase domain of the RET proto-
RT   oncogene in Hirschsprung's disease.";
RL   Nature 367:377-378(1994).
RN   [54]
RP   VARIANTS HSCR1 LEU-32; LEU-64; GLN-330 AND LEU-393.
RX   PubMed=8114939; DOI=10.1038/367378a0;
RA   Edery P., Lyonnet S., Mulligan L.M., Pelet A., Dow E., Abel L., Holder S.,
RA   Nihoul-Fkete C., Ponder B.A.J., Munnich A.;
RT   "Mutations of the RET proto-oncogene in Hirschsprung's disease.";
RL   Nature 367:378-380(1994).
RN   [55]
RP   VARIANT MEN2B THR-918.
RX   PubMed=7906417; DOI=10.1073/pnas.91.4.1579;
RA   Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E.,
RA   Wells S.A. Jr., Goodfellow P.J., Donis-Keller H.;
RT   "Single missense mutation in the tyrosine kinase catalytic domain of the
RT   RET protooncogene is associated with multiple endocrine neoplasia type
RT   2B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:1579-1583(1994).
RN   [56]
RP   VARIANTS MTC; MEN2A AND MEN2B.
RX   PubMed=8625130;
RX   DOI=10.1002/1097-0142(19950801)76:3<479::aid-cncr2820760319>3.0.co;2-m;
RA   Komminoth P., Kunz E.K., Matias-Guiu X., Hiort O., Christiansen G.,
RA   Colomer A., Roth J., Heitz P.U.;
RT   "Analysis of RET protooncogene point mutations distinguishes heritable from
RT   nonheritable medullary thyroid carcinomas.";
RL   Cancer 76:479-489(1995).
RN   [57]
RP   VARIANTS MEN2A SER-618; SER-620; ARG-634 AND TYR-634.
RX   PubMed=7860065; DOI=10.1007/bf00209399;
RA   Takiguchi-Shirahama S., Koyama K., Miyauchi A., Wakasugi T., Oishi S.,
RA   Takami H., Hikiji K., Nakamura Y.;
RT   "Germline mutations of the RET proto-oncogene in eight Japanese patients
RT   with multiple endocrine neoplasia type 2A (MEN2A).";
RL   Hum. Genet. 95:187-190(1995).
RN   [58]
RP   VARIANTS HSCR1 LEU-20; SER-93; GLN-330; TYR-609 AND ARG-620, AND VARIANT
RP   CYS-982.
RC   TISSUE=Blood;
RX   PubMed=7633441; DOI=10.1093/hmg/4.5.821;
RA   Angrist M., Bolk S., Thiel B., Puffenberger E.G., Hofstra R.M.W.,
RA   Buys C.H.C.M., Cass D.T., Chakravarti A.;
RT   "Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung
RT   disease.";
RL   Hum. Mol. Genet. 4:821-830(1995).
RN   [59]
RP   VARIANTS HSCR1.
RC   TISSUE=Leukocyte;
RX   PubMed=7581377; DOI=10.1093/hmg/4.8.1381;
RA   Attie T., Pelet A., Edery P., Eng C., Mulligan L.M., Amiel J., Boutrand L.,
RA   Beldjord C., Nihoul-Fekete C., Munnich A., Ponder B.A.J., Lyonnet S.;
RT   "Diversity of RET proto-oncogene mutations in familial and sporadic
RT   Hirschsprung disease.";
RL   Hum. Mol. Genet. 4:1381-1386(1995).
RN   [60]
RP   VARIANT MEN2B THR-918, AND VARIANT TYR-922.
RX   PubMed=8595427; DOI=10.1093/hmg/4.10.1987;
RA   Kitamura Y., Scavarda N., Wells S.A. Jr., Jackson C.E., Goodfellow P.J.;
RT   "Two maternally derived missense mutations in the tyrosine kinase domain of
RT   the RET protooncogene in a patient with de novo MEN 2B.";
RL   Hum. Mol. Genet. 4:1987-1988(1995).
RN   [61]
RP   VARIANT MTC ASP-768.
RX   PubMed=7845675;
RA   Eng C., Smith D.P., Mulligan L.M., Healey C.S., Zvelebil M.J.,
RA   Stonehouse T.J., Ponder M.A., Jackson C.E., Waterfield M.D., Ponder B.A.J.;
RT   "A novel point mutation in the tyrosine kinase domain of the RET proto-
RT   oncogene in sporadic medullary thyroid carcinoma and in a family with
RT   FMTC.";
RL   Oncogene 10:509-513(1995).
RN   [62]
RP   VARIANTS MTC ASP-768 AND LEU-804.
RX   PubMed=7784092;
RA   Bolino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T.,
RA   Chabrier G., Houdent C., Murat A., Schlumberger M., Tournaire J.,
RA   Lenoir G.M., Romeo G.;
RT   "RET mutations in exons 13 and 14 of FMTC patients.";
RL   Oncogene 10:2415-2419(1995).
RN   [63]
RP   VARIANTS HSCR1 TYR-157; LYS-359; TYR-609; ARG-620; ASN-1059 DEL AND
RP   PRO-1061.
RA   Hofstra R.M.W., Osinga J., Stulp R.P., Scheffer H., Meijers C.,
RA   Buys C.H.C.M.;
RT   "Mutations in three genes are found associated with the development of
RT   Hirschsprung disease: RET, EDNRB and EDN3.";
RL   Am. J. Hum. Genet. 59:A263-A263(1996).
RN   [64]
RP   VARIANTS HSCR1 PRO-40 AND PRO-765.
RX   PubMed=9043870; DOI=10.1159/000472232;
RA   Yin L., Seri M., Barone V., Tocco T., Scaranari M., Romeo G.;
RT   "Prevalence and parental origin of de novo RET mutations in Hirschsprung's
RT   disease.";
RL   Eur. J. Hum. Genet. 4:356-358(1996).
RN   [65]
RP   VARIANTS MTC/MEN2A.
RX   PubMed=8557249; DOI=10.1007/bf00218825;
RA   Landsvater R.M., Jansen R.P.M., Hofstra R.M.W., Buys C.H.C.M., Lips C.J.M.,
RA   van Amstel H.K.P.;
RT   "Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A,
RT   MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.";
RL   Hum. Genet. 97:11-14(1996).
RN   [66]
RP   VARIANTS MEN2A, VARIANT MTC ASP-768, AND VARIANT MEN2B THR-918.
RX   PubMed=8807338;
RX   DOI=10.1002/(sici)1098-1004(1996)8:1<64::aid-humu9>3.0.co;2-p;
RA   Kambouris M., Jackson C.E., Feldman G.L.;
RT   "Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial
RT   medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses
RT   of RET proto-oncogene mutations.";
RL   Hum. Mutat. 8:64-70(1996).
RN   [67]
RP   VARIANTS MEN2A.
RX   PubMed=8626834; DOI=10.1210/jcem.81.5.8626834;
RA   Frank-Raue K., Hoeppner W., Frilling A., Kotzerke J., Dralle H., Haase R.,
RA   Mann K., Seif F., Kirchner R., Rendl J., Deckart H.F., Ritter M.M.,
RA   Hampel R., Klempa J., Scholz G.H., Raue F., Bogner U., Brabant G.,
RA   Grussendorf M., Hartenstein C.H., Heidemann P., Hensen J., Doerr A.G.,
RA   Hoehne T., Hoernig-Franz I., Huefner M., Kress J., Langer H.J.,
RA   Lottermoser K., Schweikert H.U., Kusterer K., Menken U., Mercier J.,
RA   Oelkers W., Sauer J., Simon D., Starrach G., Ziegler R.;
RT   "Mutations of the ret protooncogene in German multiple endocrine neoplasia
RT   families: relation between genotype and phenotype.";
RL   J. Clin. Endocrinol. Metab. 81:1780-1783(1996).
RN   [68]
RP   VARIANT MEN2A HIS-GLU-LEU-CYS-634 INS.
RX   PubMed=9097963; DOI=10.1093/hmg/6.4.587;
RA   Hoeppner W., Ritter M.M.;
RT   "A duplication of 12 bp in the critical cysteine rich domain of the RET
RT   proto-oncogene results in a distinct phenotype of multiple endocrine
RT   neoplasia type 2A.";
RL   Hum. Mol. Genet. 6:587-590(1997).
RN   [69]
RP   VARIANTS HSCR1 PRO-180; GLN-313; ARG-620 AND PHE-791.
RX   PubMed=9090527;
RX   DOI=10.1002/(sici)1098-1004(1997)9:3<243::aid-humu5>3.0.co;2-8;
RA   Seri M., Yin L., Barone V., Bolino A., Celli I., Bocciardi R., Pasini B.,
RA   Ceccherini I., Lerone M., Kristoffersson U., Larsson L.T., Casasa J.M.,
RA   Cass D.T., Abramowicz M.J., Vanderwinden J.-M., Kravcenkiene I., Baric I.,
RA   Silengo M., Martucciello G., Romeo G.;
RT   "Frequency of RET mutations in long- and short-segment Hirschsprung
RT   disease.";
RL   Hum. Mutat. 9:243-249(1997).
RN   [70]
RP   VARIANT MTC ARG-618, AND VARIANT HSCR1 ARG-618.
RX   PubMed=9259198;
RX   DOI=10.1002/(sici)1098-1004(1997)10:2<155::aid-humu7>3.0.co;2-j;
RA   Peretz H., Luboshitsky R., Baron E., Biton A., Gershoni R., Usher S.,
RA   Grynberg E., Yakobson E., Graff E., Lapidot M.;
RT   "Cys 618 Arg mutation in the RET proto-oncogene associated with familial
RT   medullary thyroid carcinoma and maternally transmitted Hirschsprung's
RT   disease suggesting a role for imprinting.";
RL   Hum. Mutat. 10:155-159(1997).
RN   [71]
RP   VARIANT MEN2B PHE-883.
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=9360560; DOI=10.1210/jcem.82.11.4508;
RA   Gimm O., Marsh D.J., Andrew S.D., Frilling A., Dahia P.L.M., Mulligan L.M.,
RA   Zajac J.D., Robinson B.G., Eng C.;
RT   "Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in
RT   multiple endocrine neoplasia type 2B without codon 918 mutation.";
RL   J. Clin. Endocrinol. Metab. 82:3902-3904(1997).
RN   [72]
RP   VARIANT MTC ALA-891.
RX   PubMed=9398735; DOI=10.1210/jcem.82.12.4439;
RA   Hofstra R.M.W., Fattoruso O., Quadro L., Wu Y., Libroia A., Verga U.,
RA   Colantuoni V., Buys C.H.C.M.;
RT   "A novel point mutation in the intracellular domain of the ret
RT   protooncogene in a family with medullary thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 82:4176-4178(1997).
RN   [73]
RP   VARIANTS HSCR1 SER-174 AND TYR-197.
RX   PubMed=9094028; DOI=10.1016/s0022-3468(97)90616-3;
RA   Kusafuka T., Wang Y., Puri P.;
RT   "Mutation analysis of the RET, the endothelin-B receptor, and the
RT   endothelin-3 genes in sporadic cases of Hirschsprung's disease.";
RL   J. Pediatr. Surg. 32:501-504(1997).
RN   [74]
RP   VARIANTS MTC; MEN2A AND MEN2B, AND VARIANT SER-691.
RX   PubMed=9223675; DOI=10.1038/sj.onc.1201102;
RA   Kitamura Y., Goodfellow P.J., Shimizu K., Nagahama M., Ito K., Kitagawa W.,
RA   Akasu H., Takami H., Tanaka S., Wells S.A. Jr.;
RT   "Novel germline RET proto-oncogene mutations associated with medullary
RT   thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.";
RL   Oncogene 14:3103-3106(1997).
RN   [75]
RP   VARIANT MEN2B PHE-883.
RX   PubMed=9294615; DOI=10.1038/sj.onc.1201481;
RA   Smith D.P., Houghton C., Ponder B.A.J.;
RT   "Germline mutation of RET codon 883 in two cases of de novo MEN 2B.";
RL   Oncogene 15:1213-1217(1997).
RN   [76]
RP   VARIANT HSCR1 LEU-1039, AND VARIANT SER-691.
RX   PubMed=9497256; DOI=10.1086/301759;
RA   Amiel J., Salomon R., Attie T., Pelet A., Trang H., Mokhtari M.,
RA   Gaultier C., Munnich A., Lyonnet S.;
RT   "Mutations of the RET-GDNF signaling pathway in Ondine's curse.";
RL   Am. J. Hum. Genet. 62:715-717(1998).
RN   [77]
RP   VARIANT MTC GLY-611.
RX   PubMed=9677065;
RX   DOI=10.1002/(sici)1096-8628(19980707)78:3<271::aid-ajmg13>3.0.co;2-c;
RA   Oriola J., Paramo C., Halperin I., Garcia-Mayor R.V., Rivera-Fillat F.;
RT   "Novel point mutation in exon 10 of the RET proto-oncogene in a family with
RT   medullary thyroid carcinoma.";
RL   Am. J. Med. Genet. 78:271-273(1998).
RN   [78]
RP   VARIANT CYS-982.
RX   PubMed=9760196; DOI=10.1007/s004390050797;
RA   Svensson P.J., Anvret M., Molander M.L., Nordenskjold A.;
RT   "Phenotypic variation in a family with mutations in two Hirschsprung-
RT   related genes (RET and endothelin receptor B).";
RL   Hum. Genet. 103:145-148(1998).
RN   [79]
RP   VARIANTS MEN2A TYR-609; SER-618; ARG-620 AND TRP-620, AND VARIANTS HSCR1
RP   TYR-609; SER-618; ARG-620 AND TRP-620.
RX   PubMed=9384613; DOI=10.1093/hmg/7.1.129;
RA   Decker R.A., Peacock M.L., Watson P.;
RT   "Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10
RT   genotypes and strong genotype-phenotype correlation.";
RL   Hum. Mol. Genet. 7:129-134(1998).
RN   [80]
RP   VARIANT MEN2A CYS-ARG-THR-636 INS.
RX   PubMed=9452064; DOI=10.1002/humu.1380110143;
RA   Hoeppner W., Dralle H., Brabant G.;
RT   "Duplication of 9 base pairs in the critical cysteine-rich domain of the
RT   RET proto-oncogene causes multiple endocrine neoplasia type 2A.";
RL   Hum. Mutat. Suppl. 1:S128-S130(1998).
RN   [81]
RP   VARIANT MTC MET-804.
RX   PubMed=9452077; DOI=10.1002/humu.1380110156;
RA   Fattoruso O., Quadro L., Libroia A., Verga U., Lupoli G., Cascone E.,
RA   Colantuoni V.;
RT   "A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET
RT   proto-oncogene in two families affected by familial medullary thyroid
RT   carcinoma.";
RL   Hum. Mutat. Suppl. 1:S167-S171(1998).
RN   [82]
RP   VARIANTS MTC/MEN2A PHE-790 AND PHE-791.
RX   PubMed=9506724; DOI=10.1210/jcem.83.3.4619;
RA   Berndt I., Reuter M., Saller B., Frank-Raue K., Groth P., Grussendorf M.,
RA   Raue F., Ritter M.M., Hoeppner W.;
RT   "A new hot spot for mutations in the ret protooncogene causing familial
RT   medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.";
RL   J. Clin. Endocrinol. Metab. 83:770-774(1998).
RN   [83]
RP   VARIANTS MTC AND MEN2A.
RX   PubMed=9621513; DOI=10.1007/s100380050048;
RA   Shirahama S., Ogura K., Takami H., Ito K., Tohsen T., Miyauchi A.,
RA   Nakamura Y.;
RT   "Mutational analysis of the RET proto-oncogene in 71 Japanese patients with
RT   medullary thyroid carcinoma.";
RL   J. Hum. Genet. 43:101-106(1998).
RN   [84]
RP   VARIANTS HSCR1 LYS-626 AND GLN-813.
RX   PubMed=10090908; DOI=10.1086/302329;
RA   Auricchio A., Griseri P., Carpentieri M.L., Betsos N., Staiano A.,
RA   Tozzi A., Priolo M., Thompson H., Bocciardi R., Romeo G., Ballabio A.,
RA   Ceccherini I.;
RT   "Double heterozygosity for a RET substitution interfering with splicing and
RT   an EDNRB missense mutation in Hirschsprung disease.";
RL   Am. J. Hum. Genet. 64:1216-1221(1999).
RN   [85]
RP   VARIANTS HSCR1 ASN-1059 DEL AND PRO-1061.
RX   PubMed=10484767; DOI=10.1093/hmg/8.11.1989;
RA   Geneste O., Bidaud C., De Vita G., Hofstra R.M.W., Tartare-Deckert S.,
RA   Buys C.H.C.M., Lenoir G.M., Santoro M., Billaud M.;
RT   "Two distinct mutations of the RET receptor causing Hirschsprung's disease
RT   impair the binding of signalling effectors to a multifunctional docking
RT   site.";
RL   Hum. Mol. Genet. 8:1989-1999(1999).
RN   [86]
RP   VARIANT MTC GLU-GLU-CYS-531 INS.
RX   PubMed=10323403; DOI=10.1210/jcem.84.5.5665;
RA   Pigny P., Bauters C., Wemeau J.-L., Houcke M.L., Crepin M., Caron P.,
RA   Giraud S., Calender A., Buisine M.-P., Kerckaert J.-P., Porchet N.;
RT   "A novel 9-base pair duplication in RET exon 8 in familial medullary
RT   thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 84:1700-1704(1999).
RN   [87]
RP   VARIANT MEN2A GLY-640.
RX   PubMed=10522989; DOI=10.1210/jcem.84.10.6056;
RA   Tessitore A., Sinisi A.A., Pasquali D., Cardone M., Vitale D.,
RA   Bellastella A., Colantuoni V.;
RT   "A novel case of multiple endocrine neoplasia type 2A associated with two
RT   de novo mutations of the RET protooncogene.";
RL   J. Clin. Endocrinol. Metab. 84:3522-3527(1999).
RN   [88]
RP   VARIANTS MTC MET-804 AND LEU-844.
RX   PubMed=10826520; DOI=10.1055/s-2000-5806;
RA   Bartsch D.K., Hasse C., Schug C., Barth P., Rothmund M., Hoeppner W.;
RT   "A RET double mutation in the germline of a kindred with FMTC.";
RL   Exp. Clin. Endocrinol. Diabetes 108:128-132(2000).
RN   [89]
RP   VARIANT GLN-600.
RX   PubMed=10612852;
RX   DOI=10.1002/(sici)1098-1004(200001)15:1<122::aid-humu41>3.0.co;2-7;
RA   Saez M.E., Ruiz A., Cebrian A., Morales F., Robledo M., Antinolo G.,
RA   Borrego S.;
RT   "A new germline mutation, R600Q, within the coding region of RET proto-
RT   oncogene: a rare polymorphism or a MEN 2 causing mutation?";
RL   Hum. Mutat. 15:122-122(2000).
RN   [90]
RP   VARIANTS HSCR1 LEU-32; CYS-77; TRP-360 AND LYS-394.
RX   PubMed=10618407; DOI=10.1073/pnas.97.1.268;
RA   Bolk S., Pelet A., Hofstra R.M.W., Angrist M., Salomon R., Croaker D.,
RA   Buys C.H.C.M., Lyonnet S., Chakravarti A.;
RT   "A human model for multigenic inheritance: phenotypic expression in
RT   Hirschsprung disease requires both the RET gene and a new 9q31 locus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:268-273(2000).
RN   [91]
RP   VARIANTS MTC GLY-639; GLY-641 AND PHE-922.
RX   PubMed=11692159; DOI=10.1007/s001090100250;
RA   Kalinin V.N., Amosenko F.A., Shabanov M.A., Lubchenko L.N., Hosch S.B.,
RA   Garkavtseva R.F., Izbicki J.R.;
RT   "Three novel mutations in the RET proto-oncogene.";
RL   J. Mol. Med. 79:609-612(2001).
RN   [92]
RP   VARIANTS PHEOCHROMOCYTOMA ARG-634; GLY-634; TYR-634; SER-634; PHE-634;
RP   TRP-634 AND PHE-791.
RX   PubMed=12000816; DOI=10.1056/nejmoa020152;
RG   The Freiburg-Warsaw-Columbus pheochromocytoma study group;
RA   Neumann H.P.H., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G.,
RA   Schipper J., Klisch J., Altehoefer C., Zerres K., Januszewicz A.,
RA   Smith W.M., Munk R., Manz T., Glaesker S., Apel T.W., Treier M.,
RA   Reineke M., Walz M.K., Hoang-Vu C., Brauckhoff M., Klein-Franke A.,
RA   Klose P., Schmidt H., Maier-Woelfle M., Peczkowska M., Szmigielski C.,
RA   Eng C.;
RT   "Germ-line mutations in nonsyndromic pheochromocytoma.";
RL   N. Engl. J. Med. 346:1459-1466(2002).
RN   [93]
RP   VARIANT HIS-114.
RX   PubMed=12086152; DOI=10.1620/tjem.196.241;
RA   Kanai M., Numakura C., Sasaki A., Shirahata E., Akaba K., Hashimoto M.,
RA   Hasegawa H., Shirasawa S., Hayasaka K.;
RT   "Congenital central hypoventilation syndrome: a novel mutation of the RET
RT   gene in an isolated case.";
RL   Tohoku J. Exp. Med. 196:241-246(2002).
RN   [94]
RP   VARIANTS HIS-67; HIS-114; GLU-432; ASN-489; SER-691 AND CYS-982.
RX   PubMed=14566559; DOI=10.1007/s00439-003-1036-z;
RA   Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H.,
RA   Otaki S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W.,
RA   Nakamura T., Hayasaka K.;
RT   "Molecular analysis of congenital central hypoventilation syndrome.";
RL   Hum. Genet. 114:22-26(2003).
RN   [95]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-145; TRP-360 AND GLU-593.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [96]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-163; ASN-278; MET-292; ASN-489;
RP   SER-691; THR-749; SER-826; LEU-844; CYS-982 AND TYR-1112.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [97]
RP   VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; THR-918; LEU-1049 AND
RP   SER-1067, POSSIBLE INVOLVEMENT IN RENAL AGENESIS, AND CHARACTERIZATION OF
RP   VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; LEU-1049 AND
RP   SER-1067.
RX   PubMed=18252215; DOI=10.1016/j.ajhg.2007.10.008;
RA   Skinner M.A., Safford S.D., Reeves J.G., Jackson M.E., Freemerman A.J.;
RT   "Renal aplasia in humans is associated with RET mutations.";
RL   Am. J. Hum. Genet. 82:344-351(2008).
RN   [98]
RP   VARIANTS HSCR1 549-LYS-GLY-550 DEL; CYS-114; GLY-145; LEU-155; PRO-175;
RP   ALA-278; PRO-278; ASN-300; GLN-313; ILE-316; LEU-339; TYR-353; GLN-360;
RP   MET-397; MET-412; ARG-423; LYS-480; GLN-595; LEU-679; GLN-694; SER-783;
RP   ARG-830; THR-907; LEU-961; VAL-1052; CYS-1062 AND THR-1064, AND VARIANTS
RP   HIS-114; ASN-278 AND MET-292.
RX   PubMed=22174939; DOI=10.1371/journal.pone.0028986;
RA   So M.T., Leon T.Y., Cheng G., Tang C.S., Miao X.P., Cornes B.K., Diem N.N.,
RA   Cui L., Ngan E.S., Lui V.C., Wu X.Z., Wang B., Wang H., Yuan Z.W.,
RA   Huang L.M., Li L., Xia H., Zhu D., Liu J., Nguyen T.L., Chan I.H.,
RA   Chung P.H., Liu X.L., Zhang R., Wong K.K., Sham P.C., Cherny S.S.,
RA   Tam P.K., Garcia-Barcelo M.M.;
RT   "RET mutational spectrum in Hirschsprung disease: evaluation of 601 Chinese
RT   patients.";
RL   PLoS ONE 6:E28986-E28986(2011).
CC   -!- INTERACTION:
CC       P07949-2; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-4423689, EBI-945833;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=RET51;
CC         IsoId=P07949-1; Sequence=Displayed;
CC       Name=2; Synonyms=RET9;
CC         IsoId=P07949-2; Sequence=VSP_040735;
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   CCDS; CCDS53525.1; -.
DR   RefSeq; NP_065681.1; NM_020630.4.
DR   ProteomicsDB; 52048; -.
DR   TopDownProteomics; P07949-2; -.
DR   Ensembl; ENST00000340058.6; ENSP00000344798.4; ENSG00000165731.21.
DR   Proteomes; UP000005640; Chromosome 10.
PE   1: Evidence at protein level;
SQ   SEQUENCE   1072 AA;  119847 MW;  85868CBFCEA0D24C CRC64;
     MAKATSGAAG LRLLLLLLLP LLGKVALGLY FSRDAYWEKL YVDQAAGTPL LYVHALRDAP
     EEVPSFRLGQ HLYGTYRTRL HENNWICIQE DTGLLYLNRS LDHSSWEKLS VRNRGFPLLT
     VYLKVFLSPT SLREGECQWP GCARVYFSFF NTSFPACSSL KPRELCFPET RPSFRIRENR
     PPGTFHQFRL LPVQFLCPNI SVAYRLLEGE GLPFRCAPDS LEVSTRWALD REQREKYELV
     AVCTVHAGAR EEVVMVPFPV TVYDEDDSAP TFPAGVDTAS AVVEFKRKED TVVATLRVFD
     ADVVPASGEL VRRYTSTLLP GDTWAQQTFR VEHWPNETSV QANGSFVRAT VHDYRLVLNR
     NLSISENRTM QLAVLVNDSD FQGPGAGVLL LHFNVSVLPV SLHLPSTYSL SVSRRARRFA
     QIGKVCVENC QAFSGINVQY KLHSSGANCS TLGVVTSAED TSGILFVNDT KALRRPKCAE
     LHYMVVATDQ QTSRQAQAQL LVTVEGSYVA EEAGCPLSCA VSKRRLECEE CGGLGSPTGR
     CEWRQGDGKG ITRNFSTCSP STKTCPDGHC DVVETQDINI CPQDCLRGSI VGGHEPGEPR
     GIKAGYGTCN CFPEEEKCFC EPEDIQDPLC DELCRTVIAA AVLFSFIVSV LLSAFCIHCY
     HKFAHKPPIS SAEMTFRRPA QAFPVSYSSS GARRPSLDSM ENQVSVDAFK ILEDPKWEFP
     RKNLVLGKTL GEGEFGKVVK ATAFHLKGRA GYTTVAVKML KENASPSELR DLLSEFNVLK
     QVNHPHVIKL YGACSQDGPL LLIVEYAKYG SLRGFLRESR KVGPGYLGSG GSRNSSSLDH
     PDERALTMGD LISFAWQISQ GMQYLAEMKL VHRDLAARNI LVAEGRKMKI SDFGLSRDVY
     EEDSYVKRSQ GRIPVKWMAI ESLFDHIYTT QSDVWSFGVL LWEIVTLGGN PYPGIPPERL
     FNLLKTGHRM ERPDNCSEEM YRLMLQCWKQ EPDKRPVFAD ISKDLEKMMV KRRDYLDLAA
     STPSDSLIYD DGLSEEETPL VDCNNAPLPR ALPSTWIENK LYGRISHAFT RF
//
